In this file
A lower monthly equivalent can require a longer supply purchase. That detail matters when comparing the proposed prescription, payment schedule, and access to help.
This provider file follows the company’s published material and the questions it leaves open. It covers the care arrangement, price, cancellation boundaries, and contact routes; it does not certify the business or determine whether a treatment is appropriate for a particular person.
Understand the care arrangement
Effecty’s catalog separates compounded semaglutide and tirzepatide from branded products and other wellness treatments. It offers online clinical assessment and ongoing support. A product menu is not a personal treatment recommendation; the relevant comparison is the option the clinician proposes and the period being purchased.
Name the organizations involved in your own plan. The website operator, clinical practice, and pharmacy may be separate businesses. A patient should know which one is responsible for a medical decision, which holds the account, and which handles the medication.
Read the price in its proper context
The homepage lists semaglutide figures of $170, $150, and $130 per month and tirzepatide figures of $235, $210, and $190. Footnotes tie lower equivalents to three-month and twelve-month supply purchases. Confirm the full amount collected and how medication is dispensed across the term before comparing the smallest number.
Record the total paid today, the period it buys, and the next payment. If a figure is expressed per month but collected for several months, keep both numbers in the comparison. Our price-comparison worksheet helps separate a low initial figure from the continuing commitment.
Find the cancellation boundary
Effecty’s terms allow cancellation before a prescription is sent to the pharmacy through the secure account or hello@effecty.com. They state that paid subscription fees are non-refundable and prescription returns are not accepted for reuse. Ask how a long supply purchase is treated if the clinical plan changes.
A useful request names the next renewal and the current order separately. Ask for confirmation of both the effective cancellation date and the pharmacy status. Instructions for stopping or changing the medicine itself need to come from the treating professional.
Identify the actual prescription
The site lists both compounded and approved-brand pathways. Those should remain separate in a quote and in any comparison of evidence. A familiar ingredient name does not mean a compounded preparation has the same formulation, route, or regulatory review as a branded medicine.
FDA approval concerns a particular drug product. A compounded preparation has not received that approval, and evidence for a different formulation cannot guarantee an individual result. Read the product-approval explanation and ask questions about the exact medicine proposed.
Contact and account help
The documented email route is hello@effecty.com.
The terms use this email for cancellation before a prescription reaches the pharmacy.
Start from the official Effecty website to find its verified patient-account navigation. We have not signed into a private portal or measured its support response. Do not share passwords, access codes, payment-card details, or medical records with a review site.
Bring one concrete question to the consultation
What do I pay upfront for the advertised monthly equivalent, and what happens to the remaining commitment if treatment changes?
Write the answer beside the proposed prescription and agreement. If it describes a different product, an expired promotion, or a plan you are not eligible for, ask for clarification. Our pre-purchase checklist can help keep those questions organized.
Compare a different arrangement
The Effecty alternatives guide compares care and payment structures relevant to this file. CoreAge Rx’s first place in that list is a disclosed commercial placement, not an independent clinical ranking.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- FAQ | Effecty ↗Provider-published information · Checked September 22, 2026
- Terms of Service | Effecty ↗Provider-published information · Checked September 22, 2026
- Effecty | Unveil your best self ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026